Prostate Cancer IRE Study – PRIS
The aim of the PRIS study is to evaluate the feasibility to treat localized prostate cancer with Irreversible Electroporation (IRE) - a novel image-guided tissue ablation technology that induces cell death through short pulsed electric fields - in comparison with conventional radical treatments (surgery or radiation) through a randomized controlled trial with the primary objective to locally control the tumour with a minimum of side effects.
Irreversible Electroporation (IRE) is a novel, image-guided tissue ablation technology that induces cell death through short pulsed electric fields. Unlike thermal therapies, IRE is non-thermal and selectively targets tissue, reducing toxicity to surrounding anatomical structures. The PRIS trial aims to assess the feasibility of treating localized prostate cancer with IRE compared to conventional radical surgery, focusing on local tumor control and minimal side effects. The ethical review board approved the study, and patient inclusion began in 2022. The study is currently closed to recruitment, and we are awaiting completion of the 12-month follow-up before conducting the primary analyses and reporting the results.